Results 161 to 170 of about 3,128,159 (361)
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source
ABSTRACT The ability of individuals to cope with their environment, and therefore the likelihood that they survive and pass on their genes (i.e. fitness), is largely determined by physiological state. Tracking physiological state in wild animals, however, is challenging.
Paul Jerem, L. Michael Romero
wiley +1 more source
This study highlights the importance of germline genetic markers in predicting severe trAEs caused by nivolumab. Our findings support their potential to guide personalized immunotherapy and improve treatment safety and efficacy in advanced ccRCC and other cancers.
Tokiyoshi Tanegashima +26 more
wiley +1 more source
Targeting Autophagy for Pituitary Tumors. [PDF]
Yin E, Satou M, Tateno T.
europepmc +1 more source
Reprimo (RPRM): A Tumor Suppressor That Induces Extrinsic Apoptosis via YAP Signaling
Reprimo (encoded by RPRM) is a p53 target gene that acts as a tumor suppressor and is frequently silenced by promoter hypermethylation in various cancers. Although previously known to function intracellularly as a tumor suppressor, recent studies revealed that secreted Reprimo also induces apoptosis in neighboring cells through a novel p53‐Reprimo ...
Masahiro Takikawa, Rieko Ohki
wiley +1 more source
Return to work and factors influencing recovery after endoscopic transsphenoidal surgery for hypothalamic and pituitary tumors. [PDF]
Suzuki K +7 more
europepmc +1 more source
ABSTRACT Objective To identify the minimum dataset (MDS) for the monitoring of safety and effectiveness of GH in adults with growth hormone deficiency (AGHD). Design Systematic review and expert consensus. Methods Outcomes for AGHD were identified through a systematic literature search in PubMed, Science Direct and Cochrane.
Suet Ching Chen +26 more
wiley +1 more source

